Citigroup’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

Citigroup’s Portfolio VTAE Stock Details VTAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-11,825	Closed	-$248K	–	7502
2016 Q3	$248K	Buy	11,825 +7,465	+171%	+$86K	﹤0.01%	4499
2016 Q2	$47K	Sell	4,360 -7,500	-63%	-$64.1K	﹤0.01%	5610
2016 Q1	$79K	Buy	11,860 +5,108	+76%	+$46.5K	﹤0.01%	5842
2015 Q4	$122K	Buy	6,752 +6,692	+11,153%	+$92.1K	﹤0.01%	5209
2015 Q3	$1K	Sell	60 -112	-65%	-$1.19K	﹤0.01%	7302
2015 Q2	$2K	Sell	172 -185	-52%	-$2.51K	﹤0.01%	7216
2015 Q1	$4K	Sell	357 -702	-66%	-$9.47K	﹤0.01%	6830
2014 Q4	$18K	Buy	+1,059	New	+$15.5K	﹤0.01%	6273

Citigroup's VTAE Position: Q4 2016 in Review

Citigroup sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2016, closing a stake of 11,825 shares — an estimated $248K sold.

Citigroup first reported a position in VTAE in Q4 2014 and held it in 8 quarters. The position peaked at $248K in Q3 2016. 0 funds tracked by Wall St. Rank hold VTAE as of Q4 2016.

Citigroup reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2016 after selling out during the quarter.
Citigroup sold 11,825 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2016, an estimated $248K.
Citigroup first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q4 2014 and held it in 8 quarters.
Citigroup's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $248K in Q3 2016.
0 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2016.

Based on Citigroup's 13F filing for Q4 2016, filed 10 Feb 2017.